Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4572516
Max Phase: Preclinical
Molecular Formula: C88H131N13O25
Molecular Weight: 1771.08
Molecule Type: Unknown
Associated Items:
ID: ALA4572516
Max Phase: Preclinical
Molecular Formula: C88H131N13O25
Molecular Weight: 1771.08
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CCCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCCCC(=O)O)C(=O)O)C(=O)N(C)[C@H](CC(=O)O)C(=O)N(C)[C@@H](Cc1ccccc1)C(N)=O
Standard InChI: InChI=1S/C88H131N13O25/c1-6-7-30-65(86(119)101(5)72(53-80(112)113)87(120)100(4)71(81(89)114)50-59-27-21-20-22-28-59)97-84(117)69(51-61-54-92-64-31-26-25-29-63(61)64)95-75(105)55-93-82(115)67(48-58(2)3)98-83(116)68(49-60-34-36-62(102)37-35-60)99-85(118)70(52-79(110)111)96-77(107)57-126-47-45-124-43-41-91-76(106)56-125-46-44-123-42-40-90-73(103)39-38-66(88(121)122)94-74(104)32-23-18-16-14-12-10-8-9-11-13-15-17-19-24-33-78(108)109/h20-22,25-29,31,34-37,54,58,65-72,92,102H,6-19,23-24,30,32-33,38-53,55-57H2,1-5H3,(H2,89,114)(H,90,103)(H,91,106)(H,93,115)(H,94,104)(H,95,105)(H,96,107)(H,97,117)(H,98,116)(H,99,118)(H,108,109)(H,110,111)(H,112,113)(H,121,122)/t65-,66-,67-,68-,69-,70-,71-,72+/m0/s1
Standard InChI Key: FIIAEWHLKYMXHR-DKQBRMHGSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1771.08 | Molecular Weight (Monoisotopic): 1769.9379 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Sensfuss U, Kruse T, Skyggebjerg RB, Uldam HK, Vestergaard B, Huus K, Vinther TN, Reinau ME, Schéele S, Clausen TR.. (2019) Structure-Activity Relationships and Characterization of Highly Selective, Long-Acting, Peptide-Based Cholecystokinin 1 Receptor Agonists., 62 (3): [PMID:30624060] [10.1021/acs.jmedchem.8b01558] |
Source(1):